** Shares of cell-based therapy company THMO.O plunge
31.2% to $3.51 - 2nd biggest pct. loser across U.S. exchanges
** Company says it has entered into agreements with
healthcare-focused institutional investors for sale of its 1 mln
common shares at $3.50/shr - 30% discount to stock's last close
** The transaction will be through a registered direct
offering priced at-the-market under Nasdaq rules -
THMO urn:newsml:reuters.com:*:nPncg2lFla
** Company to employ gross proceeds of ~$3.5 mln as working
capital
** Expects to close offer on or around March 27
** THMO had 4.6 mln outstanding shares as of March 24-
Refinitiv IBES
** Stock rose 13.6% this year as of last close
(Reporting by Trisha Roy in Bengaluru)
((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3635;))